Name | Eravacycline dihydrochloride |
Synonyms | TP-434-046 TP-434 2HCl Eravacyline Eravacycline HCl ERAVACYCLINE 2HCL Eravacycline dihydrochloride Eravacycline (dihydrochloride) |
CAS | 1334714-66-7 |
Molecular Formula | C27H32ClFN4O8 |
Molar Mass | 595.02 |
Solubility | H2O |
Storage Condition | -20℃ |
Use | Introduction elacycline hydrochloride was developed by Tetraphase Pharmaceuticals and launched in the United States in August 2018. It is mainly used for the treatment of complicated intra-abdominal infections in patients aged 18 years and over. The mechanism of action of Eravacycline (elacyclin) is to bind to the 30s ribose subunit, thereby preventing the binding of amino acid residues in the elongation peptide chain and disrupting the synthesis of bacterial proteins. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.584 ml | 7.918 ml | 15.836 ml |
5 mM | 0.317 ml | 1.584 ml | 3.167 ml |
10 mM | 0.158 ml | 0.792 ml | 1.584 ml |
5 mM | 0.032 ml | 0.158 ml | 0.317 ml |